Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash & Equivalents (2016 - 2025)

Spero Therapeutics' Cash & Equivalents history spans 10 years, with the latest figure at $40.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 23.87% year-over-year to $40.3 million; the TTM value through Dec 2025 reached $40.3 million, down 23.87%, while the annual FY2025 figure was $40.3 million, 23.87% down from the prior year.
  • Cash & Equivalents reached $40.3 million in Q4 2025 per SPRO's latest filing, down from $48.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $112.9 million in Q3 2021 to a low of $31.2 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $72.0 million, with a median of $74.2 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 55.3% in 2022, then surged 85.99% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $112.6 million in 2021, then fell by 3.09% to $109.1 million in 2022, then crashed by 30.04% to $76.3 million in 2023, then tumbled by 30.71% to $52.9 million in 2024, then dropped by 23.87% to $40.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Cash & Equivalents are $40.3 million (Q4 2025), $48.6 million (Q3 2025), and $31.2 million (Q2 2025).